| REVIEW ARTICLE |
|
| Year : 2015 | Volume
: 1
| Issue : 1 | Page : 7-11 |
|
|
Adalimumab
Kinjal Deepak Rambhia, Uday Sharadchandra Khopkar
Department of Dermatology, Seth GS Medical College, KEM Hospital, Parel, Mumbai, Maharashtra, India
Correspondence Address:
Kinjal Deepak Rambhia
B-105 Kalpataru Classic, Chincholi Bunder Road, Malad West, Mumbai - 400 064, Maharashtra
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/WKMP-0110.170765
|
|
|
Adalimumab is a biological agent which acts by inhibiting tumor necrosis factor-alpha. It has been used for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and moderate to severe chronic plaque psoriasis. Various studies show good efficacy in psoriasis cases, unresponsive or partially responsive to other systemic therapies and even cases of resistance to other biologics. It has helped reduce the morbidity significantly and improved the quality of life of psoriatics. Although majority of the experience of this drug is from its use in rheumatoid arthritis, this biologic has generally been considered safe even for psoriasis and other dermatologic conditions.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
